Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHAT | P28329 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | RELA | Q04206 | 1/20 | 0.51 |
| ▸ | FBP1 | P09467 | 1/20 | 0.49 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.48 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.47 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.45 |
| ▸ | MAOB | P27338 | 4/20 | 0.45 |
| ▸ | MAOA | P21397 | 3/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9131505 | 1.00 | CHAT (0.53) | CHATCYP1A2CYP2C9RELAFBP1 | |
| SCHEMBL31149192 | 0.85 | NFE2L2 (0.41) | FBP1NFE2L2 | |
| SCHEMBL2772413 | 0.82 | CYP1A2 (0.53) | CHATCYP1A2CYP2C9RELAFBP1 | |
| SCHEMBL2772409 | 0.82 | CYP1A2 (0.53) | CHATCYP1A2CYP2C9RELAFBP1 | |
| SCHEMBL1989041 | 0.81 | CHRM5 (0.54) | CHATCYP1A2CYP2C9RELAFBP1 | |
| SCHEMBL699364 | 0.80 | CHAT (0.67) | CHATCYP1A2CYP2C9RELAFBP1 | |
| SCHEMBL699365 | 0.80 | CHAT (0.67) | CHATCYP1A2CYP2C9RELAFBP1 | |
| SCHEMBL24737367 | 0.80 | CYP1A2 (0.56) | CHATCYP1A2CYP2C9RELAFBP1 | |
| SCHEMBL2771402 | 0.80 | CYP1A2 (0.52) | CHATCYP1A2CYP2C9RELAFBP1 | |
| SCHEMBL81748 | 0.80 | CYP1A2 (0.56) | CHATCYP1A2CYP2C9RELAFBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2984055-B1 | PREPARATION OF SURFACTANTS VIA CROSS-METATHESIS | MATERIA INC (US) | 2018-10-17 | — | — | EP | disclosed |
| WO-2017197056-A1 | BROMODOMAIN TARGETING DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2017-11-16 | — | — | WO | disclosed |
| US-9758445-B2 | Preparation of surfactants via cross-metathesis | MATERIA, INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-9663459-B2 | Preparation of surfactants via cross-metathesis | MATERIA, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160219879-A1 | FUNGICIDAL COMPOSITIONS | SYNGENTA PARTICIPATIONS AG (CH) | 2016-08-04 | — | — | US | disclosed |
| US-20160219879-A1 | FUNGICIDAL COMPOSITIONS | SYNGENTA PARTICIPATIONS AG (CH) | 2016-08-04 | — | — | US | disclosed |
| US-20160186094-A1 | PREPARATION OF SURFACTANTS VIA CROSS-METATHESIS | MATERIA, INC. | 2016-06-30 | — | — | US | disclosed |
| US-20160145204-A1 | PREPARATION OF SURFACTANTS VIA CROSS-METATHESIS | MATERIA, INC. | 2016-05-26 | — | — | US | disclosed |
| US-9326513-B2 | Fungicidal compositions | SYNGENTA PARTICIPATIONS AG (CH) | 2016-05-03 | — | — | US | disclosed |
| US-9326513-B2 | Fungicidal compositions | SYNGENTA PARTICIPATIONS AG (CH) | 2016-05-03 | — | — | US | disclosed |
| US-20110046088-A1 | IMINIPYRIDINE DERIVATIVES AND THEIR USES AS MICROBIOCIDES | SYNGENTA CROP PROTECTION, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110046088-A1 | IMINIPYRIDINE DERIVATIVES AND THEIR USES AS MICROBIOCIDES | SYNGENTA CROP PROTECTION, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| WO-2008101682-A2 | IMINIPYRIDINE DERIVATIVES AND THEIR USES AS MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2008-08-28 | — | — | WO | disclosed |
| US-20070244160-A1 | 6-11 Bicyclic Ketolide Derivatives | OR YAT SUN | 2007-10-18 | — | — | US | disclosed |
| US-7169786-B2 | Isoxazoline derivatives as anti-depressants | JANSSEN-CILAG S.A. (ES) | 2007-01-30 | — | — | US | disclosed |
| US-7169786-B2 | Isoxazoline derivatives as anti-depressants | JANSSEN-CILAG S.A. (ES) | 2007-01-30 | — | — | US | disclosed |
| US-5466838-A | Catalytic reaction of olefin with oxygen in the presence of aldehyde | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1995-11-14 | — | — | US | disclosed |
| EP-0540009-B1 | Process for producing epoxides | SUMITOMO CHEMICAL CO (JP) | 1995-08-30 | — | — | EP | disclosed |
| US-5367087-A | Process for producing epoxide | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1994-11-22 | — | — | US | disclosed |
| EP-0540009-A1 | Process for producing epoxides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1993-05-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046088-A1 | IMINIPYRIDINE DERIVATIVES AND THEIR USES AS MICROBIOCIDES | CD14, MYADM, MPO | CHAT 3488/4885CYP1A2 194/4885CYP2C9 168/4885 |
| US-20070244160-A1 | 6-11 Bicyclic Ketolide Derivatives | AKR1C2, AKR1C3, AKR1C1 | CHAT 3994/4885CYP1A2 104/4885CYP2C9 11/4885 |
| US-20160186094-A1 | PREPARATION OF SURFACTANTS VIA CROSS-METATHESIS | SMURF2, EPHX2, SMURF1 | CHAT 4108/4885CYP1A2 59/4885CYP2C9 453/4885 |
| US-20160219879-A1 | FUNGICIDAL COMPOSITIONS | CYP1B1, CYP4B1, DDT | CHAT 695/4885CYP1A2 4/4885CYP2C9 12/4885 |
| US-20160145204-A1 | PREPARATION OF SURFACTANTS VIA CROSS-METATHESIS | SMURF2, SMURF1, ABCB4 | CHAT 4037/4885CYP1A2 275/4885CYP2C9 1601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.